Core Viewpoint - The company announced the termination of the "Technology Research and Development Center Construction Project" and plans to permanently supplement remaining raised funds and interest into working capital for daily operations [1] Group 1: Project Termination - The project was initially planned with an investment of 82.572 million yuan, of which 49.4616 million yuan has been invested as of December 23, leaving 42.318 million yuan unutilized [1] - The termination is attributed to the impact of public health events, leading the company to use its own funds for research equipment and building construction, resulting in no current need for significant further investment in equipment [1] - This matter does not constitute a related party transaction and is subject to shareholder meeting approval, with no objections from the sponsor institution [1]

每经AI快讯，12月26日，东方生物公告，公司首次公开发行股票募集资金投资项目之"营销网络与信息 化管理平台建设项目"已达到预定可使用状态，截至2025年12月23日，该项目累计投入募集资金8616.55 万元，节余募集资金951.63万元(含利息及理财收入，具体金额以结转时募集资金账户实际余额为准)。 公司拟将该项目结项，并将节余募集资金永久补充流动资金，用于公司日常生产经营。节余募集资金转 出后，公司将办理销户手续，注销相关募集资金专户，募集资金专户监管协议随之终止。根据相关规 定，本次事项无需提交董事会审议，公司将在年度报告中披露募集资金使用情况。 ...

Core Viewpoint - The fentanyl concept sector experienced a decline of 0.26% as of the market close on December 24, with several companies within the sector showing significant drops in stock prices [1] Market Performance - The top-performing concept sectors today included: - Terahertz: +4.02% - Commercial Aerospace: +3.60% - Satellite Navigation: +3.47% - Fentanyl: -0.26% [1] Fund Flow Analysis - The fentanyl concept sector saw a net outflow of 63 million yuan from main funds today, with six stocks experiencing significant outflows. The stock with the highest outflow was ST Renfu, which had a net outflow of 42.89 million yuan [1] - Other notable outflows included: - Enhua Pharmaceutical: -13.02 million yuan - Wanfu Biology: -5.15 million yuan - Botao Biology: -2.70 million yuan [1] - Conversely, the stocks with the highest net inflows included: - Guoyao Modern: +1.77 million yuan - Guoyao Shares: +1.47 million yuan [1] Individual Stock Performance - The following stocks within the fentanyl concept sector had notable price changes: - ST Renfu: -2.06% with a turnover rate of 1.92% - Enhua Pharmaceutical: -0.79% with a turnover rate of 0.68% - Wanfu Biology: +0.61% with a turnover rate of 0.51% - Botao Biology: -0.28% with a turnover rate of 0.74% - Guoyao Modern: +0.20% with a turnover rate of 0.51% [1]

2025年12月21日，东方生物(688298)举办成立20周年庆典。庆典仪式上，公司董事长方剑秋发表致辞， 回顾企业从浙江安吉初创到跻身全球体外诊断领域重要参与者的发展历程，向长期支持企业的合作伙 伴、科研机构及全体员工致以感谢，并围绕技术创新、市场布局与未来战略展开展望，明确了这家中国 生物医疗企业的全球化发展方向。 从零起步：扎根安吉的创业初心 2005年，东方生物在浙江安吉正式成立。安吉不仅有着得天独厚的自然环境，更有着高效的营商环境， 为这家初创企业孕育了逐梦的沃土。"我们怀揣着对生物医疗事业的执着，开启了东方生物的创业征 程，并在接下来的二十年里，逐步走向国际舞台。"方剑秋在致辞中回忆道。 20年发展历程中，全球化始终是东方生物的重要战略方向。截至2025年，公司已在全球设立50余家分子 公司，组建起近3000人的团队，其中国内员工2800余人，海外员工190余人，形成一支融合多元文化、 可服务全球客户的国际化队伍。 在生产与供应链布局上，东方生物构建了"海内外协同"的体系。国内层面，除安吉、杭州两大总部基地 外，公司在上海、南京、成都、海南等地布局生命健康产业园及医学技术转化中心，依托完整产业链 ...

Group 1 - Sichuan Chengyu's wholly-owned subsidiary plans to acquire 85% equity of Hubei Jingyi Company for 2.409 billion yuan, enhancing the company's control over highway projects [1] - Huadian Technology signed contracts worth approximately 815 million yuan with Huadian Technology Group for a wind power hydrogen production project [2] - Dongfang Cable and its subsidiary won projects totaling approximately 3.125 billion yuan, accounting for 34.37% of the company's audited revenue for 2024 [3] Group 2 - Heng Rui Medicine received approval for clinical trials of SHR-2906 injection, a self-developed biopharmaceutical aimed at weight control and metabolic regulation [4] - Qingdao Port plans to invest approximately 15.7 billion yuan in two terminal projects [5] - Jingu Co. received a notification to supply low-carbon wheels for two export models to a major domestic car manufacturer, with production expected in 2026 [6] Group 3 - ST Xingguang won a procurement project worth approximately 22.955 million yuan, accounting for 11.96% of the company's revenue for 2024 [7] - Xinbo Co. plans to jointly invest in an alloy materials research institute with partners, focusing on high-performance materials for various industries [8] - Tianqi Lithium's third-phase lithium concentrate expansion project has been completed and is undergoing trial production, with a total capacity of 2.14 million tons per year [9] Group 4 - Changfei Fiber reported that new fiber optic products related to data centers represent a small proportion of total demand [10] - Dongfang Bio's subsidiaries obtained multiple medical device registration certificates, including various testing kits [11] - Xiugang Co. plans to use up to 500 million yuan of idle fundraising for cash management in safe, liquid investment products [12] Group 5 - Jifeng Co. received a project designation for passenger car seat assemblies from a European luxury brand, with a total lifecycle value of approximately 9.8 billion yuan [13] - CanSino initiated Phase I clinical trials for a combined vaccine, completing the first subject enrollment [14] - Dayu Water-saving's subsidiary pre-won a drainage project worth 140 million yuan and another project worth 1 billion yuan [15] Group 6 - Yutong Pharmaceutical's subsidiary received clinical trial approval for YKYY032 injection for treating hyperlipoproteinemia [17] - Diweier announced the departure of a core technical personnel, impacting its technical leadership [18] - Weilang Co.'s controlling shareholder received regulatory measures from the Shandong Securities Regulatory Bureau for failing to fulfill a commitment [19] Group 7 - Xiehe Electronics invested 5 million yuan in a private equity fund focusing on hard technology sectors [20] - Phoenix Optical received a government subsidy of 4.7053 million yuan, representing 35% of its projected net profit for 2024 [21] - China State Construction reported a 0.9% year-on-year increase in new contracts signed in the first 11 months of 2025, totaling 4.0408 trillion yuan [22] Group 8 - Nanguang Energy's pumped storage power station units 1 and 2 have entered trial operation, with units 3 and 4 expected to follow by year-end [23] - Jindalai plans to invest 280 million yuan to acquire a 34% stake in Yunnan Jici Medical Technology [24] - Geer Software terminated its planned acquisition of a majority stake in Weipin Zhiyuan due to failure to reach agreement on key terms [25] Group 9 - Ningbo Fubang completed the absorption merger of its wholly-owned subsidiary, inheriting all assets and liabilities [26] - Zhongyuan Neipei signed a strategic cooperation framework agreement with Ningbo Puzhi Company for humanoid robot-related business [28] - Gongyuan Co. announced a business integration and relocation of its production lines in the East China region [29] Group 10 - Chlor-alkali Chemical's subsidiary plans to invest 2.975 billion yuan in a comprehensive utilization project for waste salt [30] - Kain Technology announced the departure of a core technical personnel, impacting its research capabilities [31] - ST Renfu received approval for clinical trials of a new drug for idiopathic pulmonary fibrosis [32] Group 11 - Sanbo Brain Science's established brain science fund has completed registration with the Asset Management Association of China [33] - Tongyou Technology plans to apply for a 70 million yuan credit line from Beijing Bank, using its property as collateral [34] - Bai Ao Intelligent signed a significant equipment sales contract worth approximately 27.5021 million yuan [35] Group 12 - ST Xinyan received all restructuring investment funds totaling 2.239 billion yuan, entering the execution phase of its restructuring plan [36] - Dalu Real Estate's subsidiary decided to terminate a planned acquisition of a 60% stake in Beijing Chengzhu Real Estate [38] - Huiyu Pharmaceutical's products received marketing approval in Italy and Norway [39]

证券代码：688298 证券简称：东方生物 公告编号：2025-064 浙江东方基因生物制品股份有限公司 关于自愿披露获得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 浙江东方基因生物制品股份有限公司（简称"东方生物"或"公司"）全资 子公司Healgen Scientific LLC（以下简称"美国衡健"）、哈尔滨东方基因生 物制品有限公司（以下简称"哈尔滨东方基因"）、上海万子健生物科技有限公 司（以下简称"万子健生物"）近日取得以下几款医疗器械产品的注册证书，相 关证书内容公告如下： 产品名称 证书编号 适用国家 预期用途 有效期 持证公司/ 或生产企业 6 项细胞因子检 测试剂盒（流式 荧光发光法） 沪械注准 20252400541 中国 适用于供医疗机构用于体外定量检 测 人 体 血 清 中 细 胞 因 子白 介 素 2 （ IL-2） 、白介素 4（ IL-4） 、 白介素 6（ IL-6） 、白介素 10 （ IL-10）、肿瘤坏死因子α（ TNF- α） 、干扰素γ（ IFN-γ） ...

格隆汇12月19日丨东方生物(688298.SH)公布,公司全资子公司Healgen Scientific LLC、哈尔滨东方基因生 物制品有限公司、上海万子健生物科技有限公司近日取得多项医疗器械产品的注册证书。 ...

Core Viewpoint - The company has obtained multiple medical device registration certificates, enhancing its product portfolio in respiratory testing and related technologies [1] Group 1: Medical Device Registrations - The company's wholly-owned subsidiary, American Hengjian, along with Harbin Oriental Gene and Wanzi Jian Bio, has acquired several medical device registration certificates [1] - The registrations include six cytokine detection kits, testosterone and prolactin testing kits, and international certifications for COVID-19 and influenza antigen combined testing kits [1] Group 2: Market Expansion - The acquisition of these certifications will improve the company's product layout in areas such as respiratory testing, time-resolved fluorescence immunochromatography, flow cytometry, and fluorescence immunoassay instruments [1] - This development is expected to facilitate the overall market expansion of related technology platform products [1] Group 3: Sales Performance - Actual sales performance will depend on the competitiveness of the products and the company's market sales capabilities [1] - Currently, it is not possible to predict the impact of these developments on the company's future operating performance [1]

中国经济网北京12月4日讯 东方生物(688298.SH)近日披露2025年第三季度报告，前三季度公司实现营业收入6.72亿元，同比增 长2.16%；归属于上市公司股东的净利润为-2.13亿元，上年同期为-2.62亿元；归属于上市公司股东的扣非净利润为-2.32亿元，上年 同期为-3.50亿元；经营活动产生的现金流量净额为-1.55亿元，上年同期为-3.67亿元。 | 人民币 | | --- | | 币种: | | 元 | | 单位: | 东方生物本次发行费用总额为8,668.22万元（不含增值税），其中承销及保荐费用6,060.16万元。 （责任编辑：关婧） 东方生物本次发行募集资金总额为63,750.00万元，募集资金净额为55,081.78万元。 东方生物最终募集资金净额比原计划少1082.16万元。东方生物2020年1月22日发布的招股说明书显示，公司拟募集资金 56,163.94万元，用于年产24,000万人份快速诊断（POCT）产品项目、技术研发中心建设项目、营销网络与信息化管理平台建设项 目、补充流动资金。 2024年，东方生物实现营业收入8.28亿元，同比增长0.95%；归属于上市公司股东的净 ...

Core Insights - The avian influenza concept sector experienced a decline of 0.76%, ranking among the top losers in the market, with major stocks like Zhongsheng Pharmaceutical hitting the limit down, while a few stocks like Wens Foodstuff and Weilan Biology saw gains of 1.80% each [1][2] Market Performance - The top-performing concept sectors included Titanium Dioxide with a gain of 4.31%, and Hainan Free Trade Zone with a gain of 3.54%, while the avian influenza sector was among the worst performers [1] - The avian influenza sector saw a net outflow of 784 million yuan, with 18 stocks experiencing net outflows, led by Zhongsheng Pharmaceutical with a net outflow of 684 million yuan [1] Stock Performance - Stocks with significant net outflows included: - Zhongsheng Pharmaceutical: -10.00% with a turnover rate of 18.78% and a net outflow of 683.65 million yuan - Yiling Pharmaceutical: -2.40% with a net outflow of 35.71 million yuan - Lianhuan Pharmaceutical: -1.79% with a net outflow of 25.69 million yuan - Hualan Biological: -6.60% with a net outflow of 18.13 million yuan [1] - Conversely, stocks with net inflows included: - Tiankang Biological: +1.26% with a net inflow of 16.52 million yuan - Shanghai Kaibao: -1.70% with a net inflow of 5.06 million yuan - Jinhai Biological: +0.16% with a net inflow of 3.82 million yuan [2]